Worldwide Clinical Experience with Ceftriaxone

Hell, K

doi:10.1159/000238674

Cited by 7 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its widespread use can be explained by its effectiveness in susceptible microorganisms infections of urinary tract, respiratory tract, skin, soft tissue, bone and joint. Also it has been used in infections in immunosuppressed patients, acute bacterial otitis media, genital infections, disseminated Lyme's disease, bacteremia/septicemia, meningitis, and in surgical prophylaxis of infections 39 . Among the acquired mechanisms of CFX resistance, the production of ESBLs is one of the most common mechanism in enterobacteria.…”

Section: Discussionmentioning

confidence: 99%

Lipid oligonucleotides as a new strategy for tackling the antibiotic resistance

Kauss

Arpin

Bientz

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Antibiotic resistance has become a major issue in public health especially for one of the most used antibiotics; the third-generation cephalosporins. one of the main resistance mechanisms in Enterobacteriaceae, is the production of extended-Spectrum β-lactamases. Here, we demonstrated that the oligonucleotide therapy is an efficient approach to reduce the resistance of bacteria to antibiotic treatment. Lipid oligonucleotides (LONs) were proved to be efficient strategies in both delivering the oligonucleotide sequences in the prokaryotic cells and decreasing the Minimum inhibitory concentration of resistant bacteria to a third generation cephalosporin, the ceftriaxone. Accordingly, we demonstrated the strong antimicrobial potential of this Lon strategy targeting the ß-lactamase activity on both clinical and laboratory strains. our results support the concept that the self-delivery of oligonucleotide sequences via lipid conjugation may be extended to other antimicrobial drugs, which opens novel ways to struggle against the antibiotic resistance.

show abstract

Section: Discussionmentioning

confidence: 99%

Lipid oligonucleotides as a new strategy for tackling the antibiotic resistance

Kauss

Arpin

Bientz

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Nevertheless, pseudolithiasis was not detected in any of the 16 patients treated with ceftriaxone whose gall bladders were examined sonographically. Although some authors recommend that doses of ceftriaxone should be lower in patients with chronic liver disease (24) because of the biliary excretion of the drug, the doses of ceftriaxone given to this group of patients have been shown to be safe, particularly if we bear in mind the fact that 2 g every 24 h is half the recommended dose for treating meningitis (13). The index of colonization by pathogens against which both antibiotics present little or no activity (E. faecalis and C. albicans) does not constitute a problem for its clinical use either.…”

Section: Discussionmentioning

confidence: 99%

“…Broad-spectrum cephalosporins which are active against gram-positive cocci and highly active against gram-negative bacilli have been the most commonly used agents (8). Ceftriaxone has an antibacterial spectrum similar to that of cefotaxime, but it presents a longer elimination half-life in plasma (8 h) and, apparently, some other pharmacokinetic advantages over cefotaxime (5,12,13). Expanded-spectrum cephalosporins have never been tested in the treatment of cirrhotic SPB, although their in vitro activities against the predominant causative organisms of SBP are excellent (22).…”

mentioning

confidence: 99%

Randomized trial comparing ceftriaxone with cefonicid for treatment of spontaneous bacterial peritonitis in cirrhotic patients

Gómez-Jiménez¹,

Ribera²,

Gasser³

et al. 1993

Antimicrob Agents Chemother

View full text Add to dashboard Cite

We compared cefonicid (2 g every 12 h) and ceftriaxone (2 g every 24 h) for their efficacy and safety in treating spontaneous bacterial peritonitis in cirrhotic patients in an open randomized clinical trial (30 patients in each group). Clinical, laboratory, and bacteriologic characteristics were similar in both groups. Ceftriaxonesusceptible strains were isolated on 44 occasions (94%), and cefonicid-susceptible strains were isolated on 43 occasions (91.5%). The antibiotic concentration in ascitic fluid/MIC ratio for ceftriaxone was > 100 throughout the dose interval (24 h), while it was lower for cefonicid (between 1 and 18). A total of 100%Y of patients treated with ceftriaxone, and 94% of those treated with cefonicid were cured of their infections (P was not significant). Hospitalization mortality was 37% in the cefonicid group and 30%o in the ceftriaxone group (P was not significant). The time that elapsed between the initiation of treatment and the patient's death was shorter in the cefonicid group patients (5.3 ± 3.90 days) than in the ceftriaxone group patients (11.8 ± 9.15 days) (P < 0.05).None of the patients presented with superinfections, and only two patients treated with cefonicid and three patients treated with ceftriaxone developed colonizations with Enterococcus faecalis or Candida albicans. Ceftriaxone and cefonicid are safe and useful agents for treating cirrhotic spontaneous bacterial peritonitis, although the pharmacokinetic characteristics of ceftriaxone seem to be more advantageous than those of cefonicid.

show abstract

Antibiotic Susceptibility of Borrelia burgdorferi In Vitro and In Vivo

Preac-Mursic¹

1993

Aspects of Lyme Borreliosis

View full text Add to dashboard Cite

Worldwide Clinical Experience with Ceftriaxone

Cited by 7 publications

References 5 publications

Lipid oligonucleotides as a new strategy for tackling the antibiotic resistance

Lipid oligonucleotides as a new strategy for tackling the antibiotic resistance

Randomized trial comparing ceftriaxone with cefonicid for treatment of spontaneous bacterial peritonitis in cirrhotic patients

Antibiotic Susceptibility of Borrelia burgdorferi In Vitro and In Vivo

Contact Info

Product

Resources

About